SHANGHAI – The 2017 Healthcare Capital and Connections Summit is an event where American biopharmas, lawyers, bankers and investors come to Shanghai to see for themselves what the China opportunity is all about. The organizers, SPD Silicon Valley Bank, Piper Jaffray and Vivo Capital, do their part to line up a complementary group of Chinese counterparts for them to meet, face to face.
SHANGHAI – The 2017 Healthcare Capital and Connections Summit is an event where American biopharmas, lawyers, bankers and investors come to Shanghai to see for themselves what the China opportunity is all about. The organizers, SPD Silicon Valley Bank, Piper Jaffray and Vivo Capital, do their part to line up a complementary group of Chinese counterparts for them to meet, face to face.
SHANGHAI – For the first time in its 12-year history, the International Conference for Rare Diseases and Orphan Drugs (ICORD) convened its annual event in China. The event marks a milestone for the local event partner, the Chinese Organization for Rare Disorders (CORD), a patient advocacy non-governmental organization that has managed to thrive in China's harsh civil society climate.
SHANGHAI – For the first time in its 12-year history, the International Conference for Rare Diseases and Orphan Drugs (ICORD) convened its annual event in China. The event marks a milestone for the local event partner, the Chinese Organization for Rare Disorders (CORD), a patient advocacy non-governmental organization that has managed to thrive in China's harsh civil society climate.
SHANGHAI – Innovent Biologics Inc., of Suzhou, has acquired the global rights for a preclinical indoleamine 2,3-dioxygenase (IDO) inhibitor discovered by the Shanghai Institute of Organic Chemistry. By adding an IDO candidate to its immuno-oncology pipeline, Innovent aims to increase the effectiveness of its PD-1 candidate currently in phase III studies in partnership with Eli Lilly and Co.. of Indianapolis.
SHANGHAI – Innovent Biologics Inc., of Suzhou, has acquired the global rights for a preclinical indoleamine 2,3-dioxygenase (IDO) inhibitor discovered by the Shanghai Institute of Organic Chemistry. By adding an IDO candidate to its immuno-oncology pipeline, Innovent aims to increase the effectiveness of its PD-1 candidate currently in phase III studies in partnership with Eli Lilly and Co.. of Indianapolis.
SHANGHAI – Last week, a day before CPhI's China Pharma Week kicked off in Shanghai with thousands of foreign drug company reps in attendance, China's drug industry received some welcome news. The CFDA was accepted as a regulatory member to the International Council of Harmonization (ICH), an important step in China's ongoing journey to become a globally leading supplier and market for quality pharmaceuticals.
SHANGHAI – Last week, a day before CPhI's China Pharma Week kicked off in Shanghai with thousands of foreign drug company reps in attendance, China's drug industry received some welcome news. The CFDA was accepted as a regulatory member to the International Council of Harmonization (ICH), an important step in China's ongoing journey to become a globally leading supplier and market for quality pharmaceuticals.
SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med), of Shanghai, presented at the recent American Society of Clinical Oncology meeting in Chicago full phase III data for fruquintinib, an oral VEGF inhibitor, for third-line colorectal cancer (CRC). The firm is now in the process of filing an NDA in China where there is no approved drug for third-line CRC. Chinese patients who have failed two prior chemo treatments are a step closer to a treatment that is less toxic and can add 2.7 months over current standard of care.
SHANGHAI – Inventisbio Inc., of Shanghai, has emerged from stealth, nabbing $19 million in series B financing from health care venture financiers Orbimed and Lilly Asia Ventures (LAV). Founded in 2015, Inventisbio has a pipeline of four small-molecule preclinical drug candidates for cancer and gout.
